CF
COGT icon

Corebridge Financial’s Cogent Biosciences COGT Stock Holding History

Corebridge Financial’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,955
Closed -$269K – 611
2025
Q1 		$269K Sell
44,955
-666
-1% -$5.22K ﹤0.01% 1897
2024
Q4 		$356K Sell
45,621
-3,443
-7% -$34.3K ﹤0.01% 1852
2024
Q3 		$530K Sell
49,064
-303
-0.6% -$2.95K ﹤0.01% 1704
2024
Q2 		$416K Buy
+49,367
New +$374K ﹤0.01% 1793

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Corebridge Financial's COGT Position: Q2 2025 in Review

Corebridge Financial sold out of Cogent Biosciences (COGT) in Q2 2025, closing a stake of 44,955 shares — an estimated $269K sold.

Corebridge Financial first reported a position in COGT in Q2 2024 and held it in 4 quarters. The position peaked at $530K in Q3 2024. 180 funds tracked by Wall St. Rank hold COGT as of Q2 2025.

  • Corebridge Financial reported no remaining Cogent Biosciences position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 44,955 Cogent Biosciences shares in Q2 2025, an estimated $269K.
  • Corebridge Financial first reported a position in Cogent Biosciences in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Cogent Biosciences position peaked at $530K in Q3 2024.
  • 180 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.